BioInvent Moves to NASDAQ Stockholm’s Mid Cap SegmentLUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV) Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022.
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumabLUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV) - Partial response in metastatic uveal melanoma, a difficult-to-treat indication - Markedly improvement of stage IV sarcoma BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from
BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma - Complete responses lasting beyond 18, 24 and 36 months LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in ChinaLUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application
BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid TumorsLUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV) - BioInvent's pipeline expanding to four drug candidates in five clinical trials Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a
Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022LUND, SWEDEN / ACCESSWIRE / November 25, 2021 / BioInvent International (STO:BINV) Lund, Sweden - November 25, 2021 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent") Annual General Meeting in 2022 have now been appointed. The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2022: - Laura
BioInvent Hosting Key Opinion Leader Webinar on BI-1206LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV) Friday, December 17 at 1 pm ET (7 pm CET) BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key
BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021LUND, SE / ACCESSWIRE / November 9, 2021 / BioInvent International (STO:BINV) Data support BT-001's unique dual mode of action BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based
BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021- BI-1206 restores rituximab activity in relapsed or refractory patients - Demonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 months LUND, SE / ACCESSWIRE / November 4, 2021 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces additional positive interim
Invitation to Presentation of BioInvent’s Interim Report January–September 2021LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV) Lund, Sweden, October 28, 2021 - BioInvent International AB (Nasdaq Stockholm: BINV) invites to a presentation of the third quarter report 2021 and a telephone conference with CEO Martin Welschof. The presentation will be held in English. When: 2:00 p.m. CEST Thursday October 28, 2021. Listen to the presentation:
BioInvent International AB Interim Report January - September 2021LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV) "The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The
BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory BoardLUND, SWEDEN / ACCESSWIRE / October 25, 2021 / BioInvent International (STO:BINV) - Holds extensive expertise in surgical oncology, immunotherapy, and drug development - Will provide valuable input as BioInvent further expands clinical pipeline of cancer drugs BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for
BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus at SITC 2021LUND, SE / ACCESSWIRE / October 1, 2021 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announce that they
